KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Receivables - Net: 2010-2025

Historic Receivables - Net for Rigel Pharmaceuticals (RIGL) over the last 9 years, with Sep 2025 value amounting to $45.9 million.

  • Rigel Pharmaceuticals' Receivables - Net rose 50.20% to $45.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.9 million, marking a year-over-year increase of 50.20%. This contributed to the annual value of $41.6 million for FY2024, which is 36.22% up from last year.
  • Rigel Pharmaceuticals' Receivables - Net amounted to $45.9 million in Q3 2025, which was up 15.08% from $39.9 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Receivables - Net ranged from a high of $142.2 million in Q1 2021 and a low of $3.0 million during Q1 2025.
  • For the 3-year period, Rigel Pharmaceuticals' Receivables - Net averaged around $29.2 million, with its median value being $29.4 million (2023).
  • In the last 5 years, Rigel Pharmaceuticals' Receivables - Net skyrocketed by 1,372.00% in 2021 and then plummeted by 89.28% in 2022.
  • Over the past 5 years, Rigel Pharmaceuticals' Receivables - Net (Quarterly) stood at $15.5 million in 2021, then grew by 29.27% to $20.0 million in 2022, then soared by 52.75% to $30.6 million in 2023, then soared by 36.22% to $41.6 million in 2024, then spiked by 50.20% to $45.9 million in 2025.
  • Its Receivables - Net stands at $45.9 million for Q3 2025, versus $39.9 million for Q2 2025 and $3.0 million for Q1 2025.